NEW YORK (GenomeWeb News) – Autism diagnostics firm SynapDx today said that it raised $15.4 million.

Google Ventures led the round with Foundation Medical Partners also a new investor. Founding investors North Bridge Venture Partners and General Catalyst Partners also participated in the round.

The funding will be used to support Lexington, Mass.-based SynapDx as it develops a blood-based diagnostic test for autism spectrum disorder. The test is designed to help clinicians identify children with autism earlier than can be currently diagnosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.